『8 Days After the FDA: Breaking Down HRT and Breast Cancer Risk with Dr. Corinne Menn』のカバーアート

8 Days After the FDA: Breaking Down HRT and Breast Cancer Risk with Dr. Corinne Menn

8 Days After the FDA: Breaking Down HRT and Breast Cancer Risk with Dr. Corinne Menn

無料で聴く

ポッドキャストの詳細を見る

今ならプレミアムプランが3カ月 月額99円

2026年5月12日まで。4か月目以降は月額1,500円で自動更新します。

概要

 On this episode of Innovate & Elevate, Sharon sits down with Dr. Corinne Menn, an OB-GYN, menopause specialist, and breast cancer survivor, to unpack one of the most misunderstood topics in women’s health: the relationship between breast cancer risk and hormone therapy. Recorded eight days after the FDA announced it will remove the long-standing black box language on hormone therapy, this conversation traces the legacy of the 2002 Women’s Health Initiative press conference, what the data actually showed, and how modern evidence can better guide women and their clinicians today.What You’ll Learn from this Episode:What really happened in July 2002, and why the WHI press conference (held eight days before doctors saw the full study) reshaped hormone therapy for a generation.The difference between estrogen alone and combined estrogen–progestin therapy, and why age, timing, and formulation matter.Why every major professional society (ASCO, ACOG, American Urological Association, The Menopause Society) agrees that local, low-dose vaginal hormones do not increase breast cancer risk, recurrence, or mortality.The role of tools like the Tyrer–Cuzick breast cancer risk model in understanding your baseline risk - and how Dr. Menn interprets those results in the context of HRT.Dr. Menn’s own story: being diagnosed with ER/PR-positive breast cancer at 28 during OB-GYN residency, going through abrupt menopause, and later discovering a BRCA2 mutation after updated genetic testingHow she now counsels breast cancer survivors about menopause, quality of life, and when hormone therapy may or may not be appropriatePractical ways women can prepare for a time-limited doctor’s visit to have more informed, individualized conversations about breast cancer risk and hormone therapyAs always, nothing in this episode is personal medical advice. Please talk with your own clinician about your individual history, risks, and options.Connect with Sharon:On LinkedInOn InstagramLearn more about the Innovate and Elevate podcastSubscribe to Innovate and Elevate on YouTubeJoin the newsletter to receive the latest episodes in your inboxConnect with Dr. Corinne Menn:On LinkedInOn InstagramLearn more on her websiteBreast Cancer Risk Models & Screening Tools:Tyrer–Cuzick (IBIS) Breast Cancer Risk Model - https://ems-trials.org/riskevaluator/ Gail Model (Breast Cancer Risk Assessment Tool) - https://bcrisktool.cancer.gov POSITIVE Trial – New England Journal of Medicine - https://www.nejm.org/doi/full/10.1056/NEJMoa2215851 Hormone Therapy, Menopause Guidelines & Professional Societies:The Menopause Society - https://www.menopause.org/ American Society of Clinical Oncology (ASCO) - https://www.asco.org/ American College of Obstetricians and Gynecologists (ACOG) - https://www.acog.org/ American Urological Association (AUA) - https://www.auanet.org/ WHI & FDA Background Materials:Women’s Health Initiative (WHI) – National Institutes of Health - https://www.nhlbi.nih.gov/science/womens-health-initiative-whi WHI 2002 Press Release - https://www.nhlbi.nih.gov/news/2002/hrtupdate Publications & Books ReferencedEstrogen Matters – Avrum Bluming & Carol Tavris - https://www.estrogenmatters.com/ Maria Shriver Sunday Paper Article - https://www.mariashriversundaypaper.com/warning-label-menopause-hormone-therapies/ FDA-Approved Therapies Mentioned:- Duavee (Conjugated Estrogens + Bazedoxifene) - https://www.duavee.com/ Intrarosa (Prasterone/DHEA) - https://www.intrarosa.com/ Micronized Progesterone (Prometrium) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20846_prometrium_lbl.pdf Clinicians Mentioned in the Episode:Dr. Rachel Rubin - https://www.rachelrubinmd.com/ Dr. Kelly Casperson - https://www.kellycaspersonmd.com/ Dr. Vonda Wright - https://www.drvondawright.com/ Dr. Sharon Malone - https://www.sharonmalonemd.com/ Dr. Heather Hirsch - https://www.heatherhirschmd.com/ Additional Trusted Medical & Genetics ResourcesAlloy Women’s Health - https://www.myalloy.com/ USPSTF Screening Guidelines https://www.uspreventiveservicestaskforce.org/ Myriad Genetics – BRCA and BART Testing - https://myriad.com/patients-families/hereditary-cancer/ National Society of Genetic Counselors (Find a Counselor) - https://www.nsgc.org/page/find-a-genetic-counselor Skip to the Good Part:00:00 – Local Vaginal Estrogen and the Black Box Barrier01:00 – Introducing Dr. Corinne Menn and the HHS Moment02:00 – What the FDA Label Change Actually Means04:00 – The 2002 WHI Press Conference and Its Fallout06:00 – Dr. Menn’s Personal Story: Cancer at 28 and Abrupt Menopause09:00 – Modern HRT vs. WHI Formulations13:30 – Time-Limited Visits and the Need for Prepared Patients21:00 – Knowing Your Baseline Breast Cancer Risk29:00 – Does HRT Cause Breast Cancer? What the Data Actually Show36:00 – Breast Cancer Survivors, Choice, and Quality of LifePlease note: The information on this podcast is for educational ...
まだレビューはありません